Fibrocell Science is an autologous cell and gene therapy company, focusing on discovering and developing therapies for diseases affecting the skin, connective tissues and joints. The Company’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.